Author: Aksoy, Elif; Oztutgan, Turgut
Title: COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature Cord-id: gjjhvuxj Document date: 2020_8_17
ID: gjjhvuxj
Snippet: Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration
Document: Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration of convalescent plasma therapy in myasthenia gravis patients with concomitant COVID-19.
Search related documents:
Co phrase search for related documents- acute exacerbation and lung damage: 1, 2, 3, 4
- low molecular weight and lung damage: 1, 2, 3, 4, 5, 6, 7
- low molecular weight heparin and lung damage: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date